-
WuXi Biologics Expands Sterile Filling Capabilities in Germany with New Line
•
China’s Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced plans to establish a new sterile filling line for prefilled syringes (PFS) at its facility in Leverkusen, Germany. This move is set to enhance the company’s drug product (DP) capabilities in the region, optimizing the facility’s…
-
Shanghai Duoning Biotechnology Partners with Branca Bunús for Transfection Reagents Innovation
•
Shanghai Duoning Biotechnology Co., Ltd, a prominent biopharmaceutical company in China, has entered into a strategic partnership with Ireland-based Branca Bunús Ltd, a leader in gene delivery technology. This collaboration aims to provide biopharmaceutical customers with innovative transfection reagents through resource sharing, focusing on the development, optimization, and application of…
-
WuXi AppTec Reports Q3 2024 Revenues of RMB 10.46 Billion Amid Biosecure Act Challenges
•
WuXi AppTec Co., Ltd (SHA: 603259), the China-based Contract Development and Manufacturing Organization (CDMO) facing potential restrictions under the Biosecure Act—set to ban drugmakers with U.S. government contracts from utilizing Chinese services post-2032—reported its financial results for the first three quarters of 2024. In the third quarter, revenues reached RMB…
-
Tianjin Municipality Unveils Plan to Boost Synthetic Biology and Biomanufacturing Innovation
•
The People’s Government of Tianjin Municipality has unveiled two significant implementation plans to bolster the bioeconomy and pharmaceutical outsourcing service industry within the region. The first plan, “Implementation Plan for Accelerating the Innovation of Synthetic Biology and Promoting the High Quality Development of the Biomanufacturing Industry in Tianjin,” aims to…
-
WuXi AppTec Addresses Media Speculation on Potential Sale of WuXi ATU
•
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359, OTCMKTS: WUXAY), a leading China-based Contract Development and Manufacturing Organization (CDMO), has issued a statement addressing media speculations about the potential sale of its cell and gene therapy segment, WuXi Advanced Therapies (WuXi ATU). The company clarified that no decision has been…
-
Ningbo Menovo Pharmaceutical Partners with Nanjing Huawe Medicine for High-End Product Development
•
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing Huawe Medicine Technology Group Co., Ltd, a move aimed at leveraging synergies in research and development (R&D) and manufacturing resources. The collaboration seeks to reduce drug development costs and enhance product competitiveness in the high-end…
-
Tigermed Announces Acquisition of Majority Stake in Shanghai Guanhe Pharmaceutical for CNY 140 Million
•
Tigermed (SHE: 300347, HKG: 3347) has announced its intention to acquire a 40.5650% stake in Shanghai Guanhe Pharmaceutical Co., Ltd (hereinafter referred to as “Guanhe Pharmaceutical”) from DiAn Diagnostics (SHE: 300244) and Suzhou Yingkai Xinyun Enterprise Management Consulting Co., Ltd (hereinafter referred to as “Suzhou Yingkai”, a subsidiary of DiAn…
-
Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy
•
Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on organoid disease models and artificial intelligence (AI), has entered into a strategic partnership with Guangzhou Jennio Biotech Co., Ltd. The collaboration aims to leverage organoid disease models and advance tumor immunotherapy drug development. Financial specifics…
-
Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape
•
South Korea’s biosimilars giant, Celltrion Inc., is gearing up to expand into the contract development and manufacturing organization (CDMO) sector, according to a company presentation this week. The announcement follows Celltrion’s founder and Chairman Seo Jung-jin’s remarks at the Morgan Stanley 22nd Annual Global Healthcare Conference last week. Seo revealed…
-
Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector
•
Itcure, a prominent gene editing specialist headquartered in Suzhou, has announced separate strategic collaborations with two domestic biotechnology companies: Lakeshore Biotechnology, a cell and gene therapy (CGT) focused biotech, and Porton Pharma Solutions, Ltd., a CGT contract research organization (CRO) and contract development and manufacturing organization (CDMO). In July, Itcure…
-
Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation
•
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a strategic partnership with Purpose Africa, a Rwanda-based platform organization comprised of experts from African academia and industry. The collaboration aims to enhance China-Africa cooperation in the realms of clinical research and digital platform development, thereby…
-
Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024
•
SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry Co., Ltd, has made a notable debut by initiating an initial public offering (IPO) on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). This marks the first pharmaceutical company to go public on this platform…
-
WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million
•
HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced its intention to acquire the remaining 30% stake in WuXi HaiDe, a non-wholly owned subsidiary specializing in comprehensive end-to-end vaccine contract research, development, and manufacturing organization services. The total consideration for this acquisition is USD…
-
WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China, has released its unaudited financial report for the first half of 2024. The company’s revenues for the period were on par with the same period in 2023, hitting RMB 8.57 billion (USD 1.2 billion), which…
-
WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has reported its financial performance for the first half of 2024, along with recent corporate developments. The company is dedicated to offering Contract Research, Development, and…
-
WuXi XDC Accelerates Bioconjugate Drug Development with 67.6% YOY Revenue Increase in H1 2024
•
HONG KONG—WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has reported a remarkable financial performance for the first half of 2024, with revenues jumping 67.6% year-on-year to RMB 1.665 billion (USD 230 million). This…
-
Evotec to Cut 400 Jobs Amid R&D Slowdown and Corporate Restructuring
•
Evotec SE (NASDAQ: EVO), a Germany-based Contract Research and Development Organization (CRO/CDMO), has announced plans to lay off approximately 400 employees as part of a corporate restructuring, citing a general industry slowdown in early R&D activity. During the company’s Q2 2024 earnings call, CEO Christian Wojczewski attributed the below-target revenue…
-
WuXi Biologics Partners with Medigene for TCR TCE Development in Refractory Tumors
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development and Manufacturing Organization (CRDMO) in China, has entered into a three-year strategic research cooperation agreement with Germany’s Medigene AG, an immuno-oncology platform company. The collaboration focuses on the design and research of T-cell receptor (TCR) mediated T cell engagers (TCEs) aimed…
-
WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges
•
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued performance for the first half of 2024, with its financial report indicating a decline in revenues and net profits. Revenues for the period stood at RMB 17.241 billion (USD 2.38 billion), marking an 8.64% year-on-year…
-
Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies
•
Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Guangzhou Geneseed Biotech Co., Ltd., a company specializing in circular RNA (circRNA)-focused CRDMO services. This collaboration aims to expedite the development of innovative circRNA therapies, enhancing technical innovation, clinical translation, and…
-
Tigermed Expands Asia Pacific Presence with Acquisition of Japanese CRO Medical Edge
•
Tigermed (SHE: 300347, HKG: 3347), a leading China-based Contract Research Organization (CRO), has announced the acquisition of Medical Edge Co., Ltd, a Japan-headquartered CRO. With this strategic move, Medical Edge will become a wholly-owned subsidiary of Tigermed, enhancing the company’s ability to provide high-quality mathematical statistics and electronic data solutions…
-
WuXi AppTec Spends Over USD 360,000 on US Lobbying Amid Biosecure Act Deliberations
•
Endpoints News has reported that WuXi AppTec Co., Ltd, (SHA: 603259) a China-based Contract Development and Manufacturing Organization (CDMO), spent at least USD 360,000 on lobbying efforts in the United States during the second quarter of 2024. This period coincided with lawmakers’ consideration of the Biosecure Act and other legislative…
-
Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas
•
Shanghai-based Lionco Pharmaceutical Group (SHA: 603669) has entered into a strategic partnership framework agreement with France’s Laboratoire Bailly-Creat, aiming to penetrate international markets. Under this collaboration, Lionco will manufacture GMP-compliant injection and solid preparation products from its portfolio at its Hainan manufacturing base for Bailly-Creat. The French company will take…
-
Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit
•
Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell therapy, has reportedly drawn the attention of a potential acquirer. This development sent Legend’s stock price climbing over 12% in a single day, as reported by the news platform Street Insider. The company has allegedly…
-
China’s HiRO Expands US Presence with Acquisition of New Jersey-Based DeltaMed Solutions
•
Harvest Integrated Research Organization (HiRO), a China-based ’boutique’ Contract Research Organization (CRO), has expanded its presence in the US through the strategic acquisition of DeltaMed Solutions. DeltaMed, located in Somerset, New Jersey, is a CRO that specializes in a suite of services including biostatistics, programming, data management and monitoring, real-world…
-
LEK Consulting’s Survey Reveals Biosecure Act’s Impact on Life Sciences Companies
•
LEK Consulting, a UK/US firm, has published the results of a global survey aimed at gauging the impact of the proposed US Biosecure Act on life sciences companies. Conducted in June 2024, the survey included a selection of biopharma firms, investors, and CROs/CDMOs. The survey revealed that 68% of respondents…
-
Suzhou Porton Biologics Becomes First Chinese CDMO to Adopt MaxCyte’s ExPERT GTx Platform
•
Suzhou Porton Biologics Ltd, a biopharmaceutical company based in China, has announced the introduction of MaxCyte, Inc.’s cGMP compliant ExPERT GTx flow electroporation technology platform, marking it as the first Contract Development and Manufacturing Organization (CDMO) in China to be equipped with this advanced system. The ExPERT GTx platform is…
-
Shanghai Fudan-Zhangjiang and Hanhui Pharmaceutical End Marketing Deal for Libaoduo
•
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a Chinese biopharmaceutical company, has reached an agreement with Hanhui Pharmaceutical Co., Ltd’s wholly-owned subsidiary to terminate the market promotion service agreement for its doxorubicin in liposome injection formulation, branded as Libaoduo. The original agreement was signed in October 2018, establishing…
-
CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally
•
CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced the successful completion of a new financing round, raising nearly RMB 100 million (USD 13.8 million). This funding round was led by prominent investors Yifeng Capital and Zhiyi Investment, with additional participation from Yuanhe Holdings…
-
Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic
•
Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership with Beijing Highthink Pharmaceutical Technology Service Co., Ltd. The collaboration is aimed at providing Contract Research Organization (CRO) services, specifically to support a clinical study for Apeloa’s generic version of semaglutide. Under the terms of…
-
Jiangxi Fushine’s Subsidiary LinkChem Eyes Hong Kong IPO Amid Strong Revenue Growth
•
Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE: 300497), a Chinese pharmaceutical company, has announced that its subsidiary, LinkChem, intends to conduct an initial public offering (IPO) on the Hong Kong Stock Exchange. At this stage, no further details regarding the IPO have been disclosed. Established in 2011 and headquartered in Shanghai,…
-
WuXi Biologics Expands Manufacturing Capacity with New Bioreactors at Hangzhou Facility
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced the successful installation of three sets of 5,000L single-use bioreactors at its drug substance manufacturing facility in Hangzhou (MFG20), which began operations in 2021. The installation of these bioreactors, compliant with Good…
-
OBiO Technology Partners with Shenzhen Innovation Immunotechnology for TCR-T Cell Therapy Development
•
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading Contract Research Organization (CRO) specializing in gene therapy based in China, has entered into a partnership with Shenzhen Innovation Immunotechnology Co., Ltd. As per the agreement, OBiO will offer preclinical pharmaceutical research services for Shenzhen Innovation’s TCR-T cell therapy candidate, SIIT-T002.…
-
Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns
•
FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that Akeso Biopharma (HKG: 9926) and partner Summit Therapeutics’ ivonescimab, a PD-1/VEGF bispecific antibody (BsAb), has become the first molecule to outperform Merck Sharp & Dohme’s (MSD) leading PD-1 therapy Keytruda (pembrolizumab) in a head-to-head trial…
-
GenScript Shares Slide on US Congressional Request for FBI Investigation
•
Shares of GenScript Biotechnology Co., Ltd (HKG: 1548), a China-based Contract Development and Manufacturing Organization (CDMO), plummeted over 17% in trading today following a request by a US House of Representatives committee on China for the FBI to investigate the company and its subsidiaries. The committee, led by chair John…
-
Parexel Partners with Ruijin Hospital Hainan Subsidiary to Enhance Real-World Evidence in Drug Development
•
Parexel, a U.S.-based contract research organization (CRO), has entered into a partnership with Shanghai Ruijin Hospital’s Hainan subsidiary. This collaboration aims to explore the use of real-world data (RWD) and real-world evidence (RWE) to facilitate the accelerated approval of drugs, thereby increasing Chinese patients’ access to innovative medications and therapies.…
-
China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition
•
Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with China’s Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347). This global collaboration is centered around the application of Veeva’s modern electronic data acquisition system, Vault EDC. The innovative digital solution is designed to enhance…
-
Jiuzhou Pharmaceutical Expands Global Footprint with $9.5 Million German CRO Subsidiary
•
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans to invest USD 9.5 million in the establishment of a wholly-owned subsidiary in Germany that will provide Contract Research Organization (CRO) services. The new unit, temporarily named Jiuzhou Pharma Europe GmbH, is anticipated to be…
-
Porton Pharma Solutions Invests €50 Million in Slovenian R&D Expansion
•
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has inaugurated a new research and development (R&D) center in Mengeš, Slovenia, marking a significant step in the company’s global expansion strategy. The investment, totaling €50 million ($54.1 million), encompasses the acquisition and comprehensive renovation of the facility, which…
-
Asymchem Laboratories Enters European Market with Pfizer’s UK API Plant and R&D Lab Purchase
•
Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading China-based Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of a state-of-the-art Active Pharmaceutical Ingredient (API) pilot plant and R&D laboratory in Sandwich, UK. These facilities, previously under the ownership of US pharmaceutical giant Pfizer, mark Asymchem’s inaugural foray…
-
Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services
•
Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced a comprehensive strategic partnership with the UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). This collaboration will encompass the entire spectrum of drug development, including small molecules, macromolecules, and gene therapies, from…
-
Porton Biologics and SAFE Collaborate to Accelerate Pharmaceutical R&D Services
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy of Sciences (CAS) in 2016, Suzhou Institute of Materia Medica, Clinical Service Center, and SPD BANK.…
-
Ribobay Pharma and General Biol to Commence GMP-Grade Oligonucleotide Manufacturing Services
•
Shanghai-based contract research, development, and manufacturing organization (CRDMO) Ribobay Pharma has announced plans to commence offering GMP-level CRDMO services for oligonucleotide manufacturing in the near future. In collaboration with its spin-off company, General Biol (Anhui) Co., Ltd, the companies aim to provide access to Cytiva’s FlexFactory platform for oligo manufacturing.…
-
BIO Surveys Members on China-CDMO Dependence Amid BioSecurity Bill Deliberations
•
The Biotechnology Innovation Organization (BIO), a prominent US industry trade group, is conducting a survey among its members to assess the extent of reliance on China-based Contract Development and Manufacturing Organizations (CDMOs), according to a report by FiercePharma.com. The survey, titled “Understanding Key Elements of the Biopharma Supply Chain,” aims…
-
Bristol-Myers Squibb Prepares Contingency Plans in Response to the Biosecure Act
•
Bristol-Myers Squibb (BMS; NYSE: BMY), a leading U.S. pharmaceutical company, is reportedly drafting ‘contingency plans’ to address the potential implications of the Biosecure Act, which is currently under legislative review in the United States. As detailed by the Financial Times, BMS’s CFO, David Elkins, disclosed on a media call that…
-
Ningbo Menovo Partners with University of Michigan to Develop GLP-1 Delivery System
•
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538), a China-based company, has announced a strategic partnership with the University of Michigan in the United States. Financial details of the collaboration remain undisclosed. The partnership will focus on developing an innovative delivery system for glucagon-like peptide-1 (GLP-1) drug targets, with the University…
-
89bio Partners with BiBio Biopharma to Build API Facility for Pegozafermin in China
•
U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and Manufacturing Organization (CDMO) BiBio Biopharma Engineering to construct an API facility in China. The facility will supply the active pharmaceutical ingredient (API) for 89bio’s lead pipeline candidate, pegozafermin, an investigational FGF21 analog currently in Phase…
-
Boehringer Ingelheim’s Shanghai Unit Secures EMA and FDA Approval for Biopharmaceutical Supply
•
Germany-based Boehringer Ingelheim has announced that its Shanghai-based Contract Manufacturing Organization (CMO), Boehringer Ingelheim Biopharmaceuticals China (BioChina), has successfully passed pre-approval inspections conducted by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). This approval allows its customer to supply biopharmaceuticals to the EU and…
-
Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation
•
Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass spectrometry and multi-omics, has successfully raised hundreds of millions of renminbi in a Series C financing round. The funding round was led by GF Xinde Investment, with participation from Sun Rock Capital. The capital raised…
-
US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties
•
Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to influence discourse surrounding China’s biotech sector. This week, Gallagher, along with Republican Raja Krishnamoorthi, sent a letter to US Defense Secretary Lloyd Austin, inquiring about updates on a Pentagon security review of several Chinese biotechnology…
-
Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production
•
Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen Pharmaceutical have entered into a comprehensive agreement with Swiss pharmaceutical giant Novartis. The agreement covers technology transfer, manufacturing, and clinical supply services for the co-developed therapy Carvykti (ciltacabtagene autoleucel; cilta-cel). As per the terms, Novartis…
-
Shenzhen Hepalink Reports 2023 Revenue Dip Amid Sector Demand Declines
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a leading pharmaceutical company based in China, has released its financial report for 2023. The company reported revenues of RMB 5.431 billion (USD 751 million), marking a decline of 24.1% year-on-year (YOY). Profits for the year reached RMB 802 million (USD 110.9…
-
WuXi AppTec Denies US Allegations of Unauthorized Intellectual Property Transfer
•
WuXi AppTec (SHA: 603259, HKG: 2359), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has found itself at the center of a controversy following allegations by US intelligence officials. According to a Reuters report, these officials claimed that WuXi AppTec had transferred a client’s intellectual property…
-
FDA Reviews Eisai’s Leqembi for Expanded Use as Monthly Alzheimer’s Therapy
•
The US Food and Drug Administration (FDA) has given the green light to review an indication extension filing for Leqembi (lecanemab), an amyloid-beta (Aβ)-targeting therapy developed by Japanese pharmaceutical company Eisai Co., Ltd. (TYO: 4523). Currently, Leqembi has conditional approval in Japan as a bi-weekly treatment for Alzheimer’s disease (AD)…
-
Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals
•
Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into separate partnerships with domestic companies Binhui Biopharmaceutical and Innoforce Pharmaceuticals Co., Ltd. In collaboration with Binhui, Medicilon aims to explore innovative areas including oncolytic viruses, nucleic acid drugs, and protein therapeutics. Meanwhile, the partnership with…
-
WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions
•
WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has released its financial report for 2023, showing a year-on-year (YOY) increase of 11.6% in revenues to RMB 17,034.3 billion (USD 2.35 billion). The company’s net profits reached RMB 3.57 billion (USD 495 million),…
-
HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups
•
China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science and biotechnology startup incubation platform; BioLabs, an international network of membership-based shared laboratory and office spaces; and MBC BioLabs, a provider of shared laboratory facilities. Recognized as a leader in DNA-encoded library (DEL) technology and…
-
WuXi XDC Reports 114.4% YOY Revenue Growth in 2023, Driven by ADC CRDMO Business
•
WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has unveiled its financial performance for 2023, reporting revenues of RMB 2.124 billion, marking a significant increase of 114.4% year-on-year (YOY), primarily driven by its antibody…
-
OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development
•
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in gene therapy, has entered into a strategic partnership with Shanghai Saierxin Biomedical Technology Co., Ltd. Under the terms of the agreement, OBiO will offer non-registered clinical trial sample preparation and testing services for Saierxin Bio’s…
-
VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology
•
VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a licensing agreement with Swiss Contract Manufacturing Organization (CMO) Lonza, securing access to Lonza’s innovative bYlok bispecific pairing technology. Financial terms of the agreement were not disclosed. Lonza’s bYlok technology addresses the prevalent industry challenge of…
-
Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy
•
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Kunshi Biotechnology (Shenzhen) Co., Ltd. The collaboration aims to expedite the Investigational New Drug (IND) filing for Kunshi’s drug candidate RR-M01, marking a significant step forward in the development of third-generation…
-
WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced plans to construct a new manufacturing base at the Tuas Biomedical Park in Singapore. This strategic expansion is designed to enhance the joint venture’s…
-
Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation
•
Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has announced a strategic merger with Silver Mars, a Suzhou-based high-tech firm specializing in bionic materials. The merged entity falls under the umbrella of YinKe Holding, a technology conglomerate with a focus on the healthcare sector.…
-
WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles
•
WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results for 2023, reporting an annual operating revenue of RMB 40.34 billion (USD 5.6 billion), representing a year-on-year (YOY) increase of 2.5%. When excluding COVID-19-related commercial projects, sales experienced a substantial growth of 25.6%. The net…
-
CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development
•
CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into a strategic partnership with Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a Contract Development and Manufacturing Organization (CDMO). This collaboration is designed to drive the development of cutting-edge technologies that align with market demands. The…
-
VectorBuilder Partners with Minaris Regenerative Medicine to Enhance Gene Therapy Solutions
•
VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership with Minaris Regenerative Medicine, a cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Japan-headquartered Showa Denko Materials Co., Ltd. This collaboration aims to integrate VectorBuilder’s superior R&D and…
-
Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform
•
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech. The collaboration aims to establish an antibody drug conjugate (ADC) platform that offers a range of diversified antibodies, highly active small molecule payloads, and linker technology. The…
-
WuXi ATU’s Philadelphia Facility Approved for Amtagvi Production Following FDA Nod
•
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec (SHA: 603259, HKG: 2359) based in China, has announced the U.S. FDA’s approval of its Philadelphia facility to commence analytical testing and manufacturing of Amtagvi (lifileucel) for Iovance. This novel therapy received accelerated approval for its Biologics License…
-
Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity
•
Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive agreement to acquire contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) for $16.5 billion. The transaction is expected to be finalized by the end of the year, pending customary regulatory conditions. This acquisition comes…
-
US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions
•
A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract development and manufacturing organizations (CDMOs) has reportedly been sidelined by the Senate this week. The bipartisan legislation, which previously triggered a significant decline in stock prices for companies like WuXi AppTec (HKG: 2359, SHA: 603259),…
-
WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced the successful completion of the inaugural manufacturing batch at its state-of-the-art drug substance facility, MFG7, located in Ireland. This milestone marks a significant step towards facilitating large-scale commercial manufacturing projects at the…
-
WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has unveiled an impressive 2023 performance forecast following its recent listing on the Hong Kong stock exchange. The company anticipates a more than 100% surge in…
-
WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has entered into a strategic partnership with Shanghai-based antibody drug conjugate (ADC) specialist, Multitude Therapeutics. Additionally, WuXi XDC has signed a memorandum of understanding (MOU) with…
-
Lonza Announces Factory Closures in the US and China Amid Global Network Optimization
•
Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans to shut down two of its factories, one in the US and another in China. The report states that this decision is made “in the context of current market dynamics” and is part of efforts…
-
China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies
•
A bipartisan bill introduced on January 26, 2024, by members of the US House Select Committee on strategic competition between the US and China has caused a significant decline in the share prices of various China-based biotech and contract development organizations (CDOs) last week. The companies have begun to respond…
-
WuXi Biologics Launches WuXiaADCC PLUS Platform for Non-Fucosylated Antibody Development
•
WuXi Biologics (HKG: 2269), a Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced the launch of a new mammalian cell line construction technology platform named WuXiaADCC PLUS. This platform is designed to be an efficient, high-yield, and high Antibody Dependent Cell Mediated Cytotoxicity (ADCC) activity platform…
-
Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services
•
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to invest USD 42 million in the establishment of a wholly-owned subsidiary in Japan that will offer Contract Research Organization (CRO) services. This strategic expansion will be executed through Jiuzhou’s existing wholly-owned subsidiary, Raybow Life Sciences（Singapore）Pte…
-
Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth
•
Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval services and fostering high-quality development in the pharmaceutical sector. The initiatives include supporting innovative R&D, providing financial incentives, enhancing inspection and testing capabilities, improving review and approval efficiency, and aiding in product promotion and standards…
-
Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development
•
The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed at fostering high-quality development in the biomedicine industry. The initiative seeks to propel Guangzhou’s biopharmaceutical sector to overcome challenges, enhance metropolitan coordination, and spearhead industry growth in the Greater Bay Area (GBA). The program extends…
-
WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent
•
WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has announced that the US Patent and Trademark Office (USPTO) has granted a patent for its proprietary engineering platform, WuXiBody. This platform is designed to significantly enhance the developability characteristics of bispecific antibodies, marking the first…
-
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
•
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered into a research service agreement with Germany’s BioNTech (NASDAQ: BNTX). As part of the collaboration, WuXi Bio will leverage its patented technology platform to develop antibodies targeting two undisclosed targets for BioNTech, aimed at advancing…
-
WuXi Biologics Expands Manufacturing Capacity to 36,000 Liters at Worcester Facility
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced a significant expansion of its manufacturing capacity at the facility located in Worcester, Massachusetts. The total manufacturing capacity at the site is set to increase to 36,000 liters, marking a substantial upgrade…
-
Frontage Laboratories Expands European Footprint with Acquisition of Accelera’s DMPK Businesses
•
Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou, and Shanghai, has announced the completion of its acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics (DMPK) businesses from Italy-based CRO Accelera S.r.l. The specifics of the deal were not disclosed. This acquisition is…
-
China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease
•
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend Global Medical Services Pte., Ltd (PharmaGend), has entered into a lease agreement with Strides Pharma Global Pte., Ltd for a manufacturing facility in Singapore, which includes the acquisition of certain production machinery and equipment. This…
-
WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has recently announced a memorandum of understanding (MOU) with South Korea-based IntoCell. The collaboration aims to comprehensively work on new toxin linker technology and contract research,…
-
CATUG Biotechnology Partners with Carcell Biopharma to Advance Nucleic Acid Drug Development
•
CATUG Biotechnology (Suzhou) Co., Ltd, a Chinese biotechnology company, has entered into a partnership with domestic firm Carcell Biopharma, a developer of medical technology service platforms. The collaboration will focus on technical cooperation in the global development of Lipid Nanoparticle (LNP) delivered mRNA and other nucleic acid drugs, aiming to…
-
Taiwan Bio and TRACT Therapeutics Forge Partnership to Combat Organ Rejection
•
Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics, focusing on cell therapies aimed at preventing allograft rejection in solid organ transplants. Under the agreement, Taiwan Bio will leverage its manufacturing expertise in cell therapy to enhance TRACT’s immune-modulating regulatory T cell therapy platform.…
-
Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced the receipt of patent approval in the United States for its proprietary core technology, the fully human antibody mice platform RenMab. This U.S. patent award comes on the heels of a similar award in China…
-
Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project
•
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a partnership with compatriot firm Asclepius Technology Company Group. The agreement, with financial details undisclosed, will see Porton provide development, production, and application services in China for Asclepius’s NK cell project, which has applications in cancer…
-
VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round
•
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of a financing round, securing close to USD 210 million with backing from Temasek, Highlight Capital (HLC), and True Light. The Viva Biotech Holdings group obtained nearly USD 150 million through the transfer of approximately 24.21%…
-
WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange
•
WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman Inc., (HKG: 2268) to the Hong Kong Stock Exchange on Friday, November 17, 2023. Through the global offer, WuXi XDC issued 178.44 million shares at a price of HK 20.60 per share. The gross proceeds…
-
Hubei Topgene Biotechnology and Shanghai Genechem Partner on Drug Toxicological Safety and Clinical Research
•
Hubei Topgene Biotechnology Co., Ltd, a China-based biotechnology company, has entered into a partnership with Shanghai Genechem Co., Ltd to collaborate on integrated drug toxicological safety evaluation, clinical research translation projects, and resource allocation. The partnership aims to leverage the strengths of both companies to enhance drug development processes. Financial…
-
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
•
Among the series of deals secured by multinational corporations at the 6th China International Import Expo (CIIE), Italy-based Chiesi Farmaceutici S.p.A. has inked a partnership with Shanghai Pharmaceuticals Co., Ltd (SHA: 601607, HKG: 2607). This strategic alliance aims to capitalize on Shanghai Pharmaceutical’s extensive distribution network. As reported by Shine,…
-
WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), is preparing for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company plans to issue 178.4 million shares, priced between HKD 19.9…
-
Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma
•
US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali Medpharma. While the financial details of the deal remain undisclosed, this strategic move significantly expands Resolian’s bioanalysis laboratory capabilities to China, complementing its existing operations in the US, UK, and Australia. This expansion allows Resolian’s…
-
Strategic Alliance Formed by uBriGene, Fraserna, and Virogin for Cell and Gene Therapy Services
•
In a significant move to bolster the cell and gene therapy (CGT) sector, China-based biotechnology firms uBriGene, Fraserna, and Virogin have entered into a strategic partnership agreement. While the financial details of the agreement remain undisclosed, the collaboration is poised to integrate the global resources of the three companies, offering…
-
Shanghai Pharmaceuticals Partners with Asymchem for Advanced Drug Development and Production
•
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a strategic partnership with compatriot firm Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a leading Contract Development and Manufacturing Organization (CDMO). This collaboration will span synthetic biotechnology, continuous reaction technology, and the development and production of…
-
Foundation Medicine Expands Genomic Profiling Partnership with Sequanta Technologies in China
•
US-based Contract Research Organization (CRO) Foundation Medicine Inc. has announced the expansion of its existing partnership with Chinese firm Sequanta Technologies Co., Ltd, to provide genomic profiling services in support of clinical research and development of oncology therapies in China. Historical Collaboration and Future PlansSince 2014, Foundation Medicine has utilized…
-
WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain
•
WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has entered into a strategic cooperation framework agreement with Hong Kong Science and Technology Parks Corp. The partnership aims to promote the establishment of a Contract Research, Development,…
-
Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron’s expansion into the Southeast Asian market, aiming to provide…
-
Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development
•
German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions’ Shanghai unit. The collaboration aims to develop a next-generation integrated antibody drug conjugate (ADC) platform technology, marking a significant step in the advancement of oncology treatments.…
-
WuXi Biologics Launches WuXiUI: A Revolutionary Biotech Patent Platform
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the launch of its innovative biotechnology patent platform, WuXiUI. Developed based on the ultra-enhanced flow plus cell culture process, this platform is designed to be suitable for mainstream cell lines and various molecular types, marking a…
-
BMS Expands CAR-T Collaboration with Cellares on Automation Tech
•
Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares, a company specializing in automated manufacturing platforms for cell therapies. This marks the second collaboration between the two entities, focusing on the production of an unnamed CAR-T cell therapy. The agreement highlights BMS’s commitment to…
-
Apeloa Pharmaceutical Expands Global Footprint with Apeloa Europe GmbH in Germany
•
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced an investment of USD 2 million to establish a wholly owned subsidiary, Apeloa Europe GmbH, in Germany. This strategic move is aimed at deepening the company’s globalization strategy, expanding its global market presence, and enhancing…
-
ZhenGe Biotech Partners with Glyco-Therapy to Develop Antibody Drug Conjugate Platform
•
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has announced a strategic partnership with domestic firm Glyco-Therapy. This collaboration aims to create a comprehensive resource cooperation and service platform for the development of next-generation antibody drug conjugates (ADCs). Innovative Approach to ADC Development The partnership will focus on the…
-
Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development
•
China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation with South Korean biotech firm Panolos Bioscience. The partnership aims to accelerate the development of multi-specific proteins, although no financial details have been disclosed. Focus on Multi-Specific TherapeuticsPanolos Bioscience is a biopharmaceutical company specializing in…
-
WuXi XDC Expands Manufacturing Capacity with New GMP Facilities in Wuxi
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement of GMP manufacturing at its state-of-the-art commercialization facilities, XBCM2 and XDP2, located in Wuxi. This development is anticipated to double the company’s…
-
Suzhou Acumen Biomedical Secures $13.8 Million in Series A+ Funding Round
•
China’s Suzhou Acumen Biomedical Technology Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The round was led by Qiandao Investment Fund, with participation from Broad Resource Investment. The funds raised will be allocated towards the expansion of the company’s…
-
Canton Biologics Secures Over RMB 300 Million in Series C Financing for Expansion
•
Canton Biologics Co., Ltd, a Guangzhou-based Contract Development and Manufacturing Organization (CDMO) specializing in biologic drugs, has reportedly raised over RMB 300 million (USD 27.5 million) in a Series C financing round. The round was led by SDIC Venture Capital, with additional investments from Guangdong Technology Financial Group, Taipu Life…
-
Shanghai Haoyuan Chemexpress Aims to Raise RMB 1.16 Billion with Convertible Bonds
•
China-based Contract Development and Manufacturing Organization (CDMO) Shanghai Haoyuan Chemexpress Co., Ltd (SHA： 688131) has announced plans to raise up to RMB 1.16 billion (USD 160 million) through the issuance of an undisclosed amount of convertible bonds (CDs). This strategic financing move is expected to strengthen the company’s financial position…
-
iotaSciences Partners with Quantum Design China for Single-Cell Handling Platform Distribution
•
UK-based cell-line engineering firm iotaSciences has announced an exclusive partnership with Quantum Design China, a subsidiary of US-based Quantum Design International. Under this agreement, Quantum Design will provide distribution services for iotaSciences’ proprietary single-cell handling platforms within China. iotaSciences’ Single Cell Handling Technologies and Their ApplicationsiotaSciences specializes in the production…
-
Asymchem Laboratories Secures RMB 2.31 Billion Private Placement with Hill House Capital Subscription
•
Asymchem Laboratories (Tianjin) Co., Ltd, a renowned Contract Development and Manufacturing Organization (CDMO) based in China and listed on the SZSE under the ticker (002821), has unveiled a significant private placement initiative. The company will issue 18,700,000 A shares at a price of RMB 123.56 per share. Hill House Capital,…
